Jeffrey Iliff, a neurologist at the University of Washington, says the trials are being paid for by the U.S.
The hope is that we could get better brain cleaning with less sleep, or even get some of that benefit while we’re awake.ĭr. Researchers want to see if they can enhance the glymphatic process with an electronic headband that would stimulate your brain in just the right way.
If you don’t sleep enough, you don’t just feel foggy you’re at higher risk for depression, headaches, and possibly dementia. As you sleep, your brain relaxes and lets extra cerebral spinal fluid wash through it, flushing away the cellular waste that accumulates throughout the day.
The overall results reveal the great potential of this class of nanovectors of DRV for an efficacious treatment of HANDs.Levendovszky designed this MRI scan to teach us more about how brains clean themselves during sleep, to better understand the glymphatic system. The assay on the BBB artificial model showed that a larger amount of DRV was able to cross BBB when incorporated in the PLGA NPs and to exert an enhanced inhibition of matrix metalloproteinase-9 (MMP-9) expression levels with respect to free DRV. Biodegradable poly(lactic- co-glycolic) acid (PLGA)-based nanoformulations resulted characterized by an average hydrodynamic size less than 150 nm, relevant colloidal stability in aqueous medium, satisfactory drug encapsulation efficiency, and retained emitting optical properties in the visible region of the electromagnetic spectrum. The aim of this study was to synthesize biodegradable polymeric NPs loaded with DRV and luminescent, nontoxic carbon dots (C-Dots) and investigate their ability to permeate through an artificial BBB and to inhibit in vitro matrix metalloproteinase-9 (MMP-9) that represents a factor responsible for the development of HIV-related neurological disorders. Therefore, innovations in DRV formulations, based on its encapsulation in optically traceable nanoparticles (NPs), may improve its transport through the BBB, providing, at the same time, optical monitoring of drug delivery within the CNS. The antiretroviral drug darunavir (DRV) has been approved for therapy of HIV-infected patients, but its efficacy in the treatment of HIV-associated neurological disorders (HAND) is limited due to the low penetration through the blood–brain barrier (BBB). Human immunodeficiency virus (HIV) can independently replicate in the central nervous system (CNS) causing neurocognitive impairment even in subjects with suppressed plasma viral load.
0 kommentar(er)
